Combined behavioral therapy and pharmacotherapy of agoraphobia

Journal of Psychiatric Research

Volumn 27, Issue SUPPL. 1, 1993, Pages 179-191

  Mavissakalian, Matig ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPRAMINE;

AGORAPHOBIA; BEHAVIOR THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PANIC; PERSONALITY; PRIORITY JOURNAL;

AGORAPHOBIA; BEHAVIOR THERAPY; COMBINED MODALITY THERAPY; DESENSITIZATION, PSYCHOLOGIC; FOLLOW-UP STUDIES; HUMANS; IMIPRAMINE; TREATMENT OUTCOME;

EID: 0027761964     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/0022-3956(93)90027-Y     Document Type: Article

References (41)

1. Biochemical indices of lactate-induced panic: A preliminary report
2. Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks
3. Two-year follow-up of agoraphobics after exposure and imipramine
4. Placebo response in panic disorder
5. Experimental induction of panic attacks
6. Self-treatment of agoraphobia by exposure
7. A neuroanatomical hypothesis for panic disorder
8. Agoraphobia: A critical review of the concept
9. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms
10. Imipramine and chlordiazepoxide in depressive and anxiety disorders—II: Efficacy in anxious outpatients
11. Anxiety in the effects of sodium lactate assessed clinically and physiologically
12. Anxiety reconceptualized
13. Comparison of alprazolam and cognitive behavior therapy in the treatment of panic disorder: A preliminary report
14. Agoraphobia: clinical features, pathophysiology, and treatment
15. Recent advances in the psychopharmacological treatment of anxiety disorders
16. Imipramine and brief therapist-aided exposure in agoraphobics having self-exposure homework
17. Exposure treatment of agoraphobia
18. Agoraphobia: behavioral therapy and pharmacotherapy
19. Imipramine in agoraphobia
20. Initial depression and response to imipramine in agoraphobia
21. The placebo effect in agoraphobia—II
22. Sequential combination of imipramine and self-directed exposure in the treatment of panic disorder with agoraphobia
23. Phobia: an overview
24. DSM-III personality disorder in agoraphobia—II: Changes with treatment
25. Relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine
26. Two-year follow-up of exposure and imipramine treatment of agoraphobia
27. Pharmacological treatment of agoraphobia: imipramine vs imipramine with programmed practice
28. Cognitive-behavioral treatment of agoraphobia: Paradoxical intention vs self-statement training
29. Imipramine in the treatment of agoraphobia: Dose response relationships
30. Imipramine dose-response relationship in panic disorder with agoraphobia
31. The relationship of plasma imipramine and N-desmethylimipramine to improvement in agoraphobia
32. Cognitive, behavioral and psychophysiological treatments of agoraphobia: A comparative outcome investigation
33. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine, and placebo
34. Combined pharmacological and behavioral treatment for agoraphobia
35. Behavior therapy, supportive psychotherapy, imipramine, and phobias
36. Treatment of agoraphobia with group exposure in vivo and imipramine
37. Treatment of phobias—I: Comparison of imipramine hydrochloride and placebo